Researchers from the Virginia Tech School of Neuroscience are teaming with the University in San Diego and the U.S. National Institutes of Health to develop a drug- now in its earliest stages- that can treat certain types of chronic pain without the addictive consequences of opioids. The drug compound, known as ML351, was discovered by researchers from the NIH, part of the U.S. Department of Health and Human Services.
It is designed to inhibit the naturally produced enzyme 15-Lipoxygenase-1, which synthesizes bioactive lipids that contribute directly to chronic pain not relieved by common over-the-counter nonsteroidal anti-inflammatory drugs such as ibuprofen. This lack of relief can lead patients to resort to more powerful drugs including opioids such as Oxycodone and other narcotics. "Our goal is to demonstrate the preclinical efficacy of ML351 for chronic pain that does not respond…
